by Alex Kadhim
A comprehensive review from the ASTCT–NMDP ACCESS Initiative highlights persistent disparities in access to hematopoietic cell transplantation and CAR T therapy, revealing how race, age,...
by Alex Kadhim
A phase I study demonstrates that dual-targeted BCMA and GPRC5D CAR T therapy is feasible and active in relapsed/refractory multiple myeloma, achieving high response rates with manageable...
by ASTCT Talks and Oncology On the Go
In a cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy’s (ASTCT) program ASTCT Talks, Terri Lynn...
by ASTCT Talks
In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD, BCOP, Clinical Pharmacy Specialist in the Stem Cell Transplantation and Cellular Therapy Department at The University of Texas MD...
by Alex Kadhim
A recent study published in The Lancet Haematology has demonstrated that patients with aggressive B-cell lymphomas experience a substantial burden of symptoms shortly after CAR T-cell infusion,...
by Alex Kadhim
Researchers at the University of Pennsylvania have found that CAR T-cell therapy response in recurrent glioblastoma (GBM) is affected by divergent remodeling of the immune system.